Stay updated with breaking news from Thomask Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 -- AIM ImmunoTech Inc. today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
Topline data expected as early as Q1 2024...
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...
OCALA, Fla., July 05, 2023 -- AIM ImmunoTech Inc. , an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
Live moderated video webcast on Wednesday, July 12th at 11:00 AM ET...